13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001791827
Total reported value
$624.4M
$624.4M
43 檔
38.0%
As reported in its official Q3 2025 Form 13F filing, Avidity Partners Management LP's tracked investment portfolio stood at $624.4M with 43 total positions.
In Q3 2025, Avidity Partners Management LP adopted a defensive or profit-taking posture, trimming 14 positions and completely liquidating 38 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 28.70% | -2.91% | +83.84% | |
| 2 | CGON | Cg Oncology Inc | Stock-Other | 14.68% | -1.75% | +6.73% | |
| 3 | MDT | Medtronic plc | Stock-Healthcare | 4.13% | -0.87% | — | |
| 4 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.65% | -0.21% | -48.94% | |
| 5 | ORKA | Oruka Therapeutics Inc | Stock-Other | 2.89% | +4.04% | +87.55% | |
| 6 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 2.64% | — | — | |
| 7 | NTRA | Natera Inc | Stock-Healthcare | 2.58% | -0.36% | EXIT | |
| 8 | DHR | Danaher CORP | Stock-Healthcare | 2.47% | — | -39.02% | |
| 9 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 2.34% | -1.66% | -26.03% | |
| 10 | CATX | Perspective Therapeutics Inc | Stock-Other | 2.34% | -1.67% | +61.09% | |
| 11 | JBIO | Jade Biosciences Inc | Stock-Other | 2.21% | +2.06% | — | |
| 12 | PFE | Pfizer Inc | Stock-Healthcare | 2.12% | — | — | |
| 13 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 2.09% | — | -36.15% | |
| 14 | CNTX | Context Therapeutics Inc | Stock-Other | 1.98% | -2.21% | +20.12% | |
| 15 | GMAB | Genmab A/s -sp Adr | Stock-Other | 1.73% | -0.05% | -61.83% | |
| 16 | ✓ | Stock-Other | 1.67% | — | — | ||
| 17 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.40% | -0.21% | EXIT | |
| 18 | ARVN | Arvinas Inc | Stock-Other | 1.35% | — | +187.20% | |
| 19 | COR | Cencora Inc | Stock-Healthcare | 1.35% | — | -42.07% | |
| 20 | EHC | Encompass Health CORP | Stock-Healthcare | 1.21% | -0.14% | -43.38% | |
| 21 | JNJ | Johnson & Johnson | Stock-Healthcare | 1.13% | — | — | |
| 22 | CI | THE Cigna Group | Stock-Healthcare | 1.09% | — | — | |
| 23 | ABBV | Abbvie Inc | Stock-Healthcare | 1.04% | — | — | |
| 24 | MCK | Mckesson CORP | Stock-Healthcare | 1.02% | — | -57.04% | |
| 25 | CARL | Carlsmed Inc | Stock-Other | 0.98% | — | — | |
| 26 | KVUE | Kenvue Inc | Stock-Consumer Staples | 0.98% | -0.35% | EXIT | |
| 27 | VTLUSD | Immunic Inc | Stock-Other | 0.94% | -1.51% | EXIT | |
| 28 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.92% | — | -20.00% | |
| 29 | EXK | Exact Sciences CORP | Stock-Materials | 0.92% | — | -79.27% | |
| 30 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 0.82% | -0.21% | -71.25% | |
| 31 | RGEN | Repligen CORP | Stock-Healthcare | 0.71% | -0.16% | -78.12% | |
| 32 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.70% | -0.06% | EXIT | |
| 33 | ASND | Ascendis Pharma A/S | Stock-Other | 0.66% | — | — | |
| 34 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.65% | +1.29% | +1141.59% | |
| 35 | BEAM | Beam Therapeutics Inc | Stock-Other | 0.62% | — | -72.64% | |
| 36 | SCYXEUR | Scynexis Inc | Stock-Other | 0.59% | -0.39% | EXIT | |
| 37 | HQY | Healthequity Inc | Stock-Healthcare | 0.55% | — | -72.50% | |
| 38 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.50% | — | — | |
| 39 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.49% | — | -50.51% | |
| 40 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.44% | — | -69.78% | |
| 41 | INSM | Insmed Inc | Stock-Healthcare | 0.38% | — | -80.34% | |
| 42 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.20% | +0.93% | — | |
| 43 | IMRX | Immuneering CORP - Class A | Stock-Other | 0.14% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics Inc | +22.8% | +83.84% | Add |
| 2 | CGON | Cg Oncology Inc | +10.1% | +6.73% | Add |
| 3 | ORKA | Oruka Therapeutics Inc | +2.2% | +87.55% | Add |
| 4 | CATX | Perspective Therapeutics Inc | +1.5% | +61.09% | Add |
| 5 | CNTX | Context Therapeutics Inc | +1.1% | +20.12% | Add |
| 6 | TEVA | Teva Pharmaceutical-sp Adr | +0.9% | -26.03% | Add |
| 7 | DHR | Danaher CORP | +0.7% | -39.02% | Add |
| 8 | TMO | Thermo Fisher Scientific Inc | +0.6% | -36.15% | Add |
| 9 | ELVN | Enliven Therapeutics Inc | +0.6% | +1141.59% | Add |
| 10 | SCYXEUR | Scynexis Inc | +0.4% | +172.64% | Add |
| 11 | ACAD | Acadia Pharmaceuticals Inc | +0.2% | — | Trim |
| 12 | GMAB | Genmab A/s -sp Adr | +0.1% | -61.83% | Trim |
| 13 | KPTI | Karyopharm Therapeutics Inc | +0.1% | — | Unchanged |
| 14 | VTLUSD | Immunic Inc | 0% | -16.32% | Add |
| 15 | AKRO | Akero Therapeutics Inc | — | -69.78% | Trim |
| 16 | PHAT | Phathom Pharmaceuticals Inc | -0.1% | -71.25% | Trim |
| 17 | ARVN | Arvinas Inc | -0.2% | +187.20% | Trim |
| 18 | NTRA | Natera Inc | -0.6% | -64.68% | Trim |
| 19 | COR | Cencora Inc | -0.7% | -42.07% | Trim |
| 20 | HQY | Healthequity Inc | -0.8% | -72.50% | Trim |
| 21 | XENE | Xenon Pharmaceuticals Inc | -1% | -50.51% | Trim |
| 22 | INSM | Insmed Inc | -1.2% | -80.34% | Trim |
| 23 | EXK | Exact Sciences CORP | -2% | -79.27% | Trim |
| 24 | BEAM | Beam Therapeutics Inc | -2% | -72.64% | Trim |
| 25 | BSX | Boston Scientific CORP | -2.8% | -48.94% | Trim |
| 26 | UNH | Unitedhealth Group Inc | -3.6% | -44.38% | Trim |
| 27 | HUM | Humana Inc | — | EXIT | Sold out |
| 28 | MDT | Medtronic plc | — | NEW | New buy |
| 29 | SNDX | Syndax Pharmaceuticals Inc | — | EXIT | Sold out |
| 30 | REGN | Regeneron Pharmaceuticals | — | EXIT | Sold out |
| 31 | GKOS | Glaukos CORP | — | EXIT | Sold out |
| 32 | DXCM | Dexcom Inc | — | EXIT | Sold out |
| 33 | RARE | Ultragenyx Pharmaceutical In | — | EXIT | Sold out |
| 34 | BMY | Bristol-myers Squibb Co | — | NEW | New buy |
| 35 | JAZZ | Jazz Pharmaceuticals plc | — | EXIT | Sold out |
| 36 | JBIO | Jade Biosciences Inc | — | NEW | New buy |
| 37 | THC | Tenet Healthcare CORP | — | EXIT | Sold out |
| 38 | NBIX | Neurocrine Biosciences Inc | — | EXIT | Sold out |
| 39 | PFE | Pfizer Inc | — | NEW | New buy |
| 40 | AXSM | Axsome Therapeutics Inc | — | EXIT | Sold out |
| 41 | OGN | Organon & Co | — | EXIT | Sold out |
| 42 | XBI | Ss Spdr S&p Biotech ETF | — | EXIT | Sold out |
| 43 | 260 | Centessa Pharmaceuticals-adr | — | EXIT | Sold out |
| 44 | RVMD | Revolution Medicines Inc | — | EXIT | Sold out |
| 45 | ✓ | — | NEW | New buy | |
| 46 | AVTR | Avantor Inc | — | EXIT | Sold out |
| 47 | IDYA | Ideaya Biosciences Inc | — | EXIT | Sold out |
| 48 | DOCS | Doximity Inc-class A | — | EXIT | Sold out |
| 49 | JANX | Janux Therapeutics Inc | — | EXIT | Sold out |
| 50 | 2655787D | Blueprint Medicines CORP | — | EXIT | Sold out |
According to official SEC Form 13F filings, Avidity Partners Management LP reported a total U.S. public equity portfolio value of $624.4M across 43 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including DNTH, CGON, MDT) accounted for 38.0% of total reported equity market value during Q3 2025.
Top New Position Initiated
MDT
市值: $18.2M
Top Position Liquidated / Trimmed
HUM
前期市值: $42.6M
During Q3 2025, Avidity Partners Management LP's top holdings by market value included DNTH (28.7%)、CGON (14.7%)、MDT (4.1%). The largest single position, DNTH, represented 28.7% of total portfolio value.
In Q3 2025, Avidity Partners Management LP made 80 total portfolio adjustments, initiating 17 new buys, adding to 11 positions, trimming 14 holdings, and fully liquidating 38 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.